LABCORP HOLDINGS INC. - Director's Dealing 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LABORATORY CORP OF AMERICA HOLDINGS (LH)
CIK: 0000920148
Period of Report: 2019-02-07

Reporting Person: Ratliff John D (CEO, Covance Drug Development)

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-02-07	Common Stock	M	1863	—	Acquired	11261	Direct
2019-02-07	Common Stock	F	556	$147.46	Disposed	10665	Direct

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-02-07	Restricted Stock Unit	$	M	1863	Disposed		Common Stock (1863)	Direct

Security	Shares	Ownership
Common Stock	40	Indirect
Common Stock	80	Indirect

F1: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2: Stock withholding to satisfy tax withholding obligations.

F3: In prior Section 16 reports shares were previously also reported in shares shown as directly owned.

F4: The reporting person is not a trustee of the irrevocable trust and disclaims beneficial ownership of the shares.

F5: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on 2/7/18.

F6: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.